A multiple ascending dose, phase1b study to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of lesigercept, a long-acting IgETrap-Fc fusion protein, in participants with atopy or allergic diseases.
BACKGROUND Lesigercept (also known as YH35324) has shown favorable safety, dose-proportional pharmacokinetics (PK), and sustained suppression of serum free immunoglobulin E (IgE) after single dosing in participants with atopy. We examined these outcomes following repeated dosing in participants with atopy or allergic d...